349 results
Showing 1–20 · 0.30 seconds · RSS
Therapeutic Advances in Psychopharmacology
Scopus
ISSN 2045-1261 · SAGE Publishing · 349 articles in the index
-
Journal Article
Repurposing incretin-based therapies for alcohol use disorder: a systematic review of efficacy and safety relative to standard pharmacotherapies in a recent comparative context
Background: Alcohol use disorder (AUD) affects millions worldwide, but current treatments, such as disulfiram, naltrexone, acamprosate, and topiramate, have limitations in efficacy and tolerability. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used for diabetes and obesity, may…
-
Journal Article
The pharmacotherapeutic use of clozapine in older adults: A narrative review
Clozapine remains the gold-standard treatment for refractory schizophrenia, yet its use in older adults is often limited by concerns regarding tolerability, age-related pharmacokinetic changes, and the burden of medical comorbidities. This narrative review synthesises current evidence on clozapine…
-
Journal Article
Incidence of antidepressant withdrawal reactions: A prospective longitudinal cohort study in primary care patients
Background The incidence of antidepressant withdrawal reactions in longer-term users and the influence of dosage is insufficiently understood. Objectives Informed by neuropharmacological models and user surveys, this study examined change in withdrawal symptoms during tapering and if increases were…
-
Journal Article
A systematic review of case reports and case series of zolpidem in the diagnosis and treatment of catatonia
Background Catatonia, commonly seen in psychiatric and medical practice, is often associated with increased morbidity and mortality. The neurotransmitter systems involved in catatonia include GABA, dopamine and glutamate. Benzodiazepines such as lorazepam, which act on GABA-A receptors, are used to…
-
Journal Article
Expert opinion survey on the pharmacological treatment of insomnia in Japan (2025)
Background Rapidly evolving insomnia management with orexin receptor antagonists (ORAs) has outpaced current clinical guidelines. Objectives This study aimed to provide a practical expert opinion reflecting specialists’ collective experience to bridge the gap between existing recommendations and…
-
Journal Article
Readability of informed consent forms from ClinicalTrials.gov in ketamine clinical trials for mental health conditions: a cross-sectional analysis
Background: Ensuring participants understand informed consent forms (ICFs) is a core ethical requirement of clinical research, particularly in psychiatry, where cognitive and affective symptoms can compromise decisional capacity. As ketamine-based interventions are increasingly studied for mental…
-
Journal Article
Patient-centred education for ketamine and esketamine therapies in mood disorders
Treatment-resistant depression (TRD) and bipolar depression (TRBD) are severe, heterogeneous mood disorders associated with substantial functional impairment, elevated suicide risk and persistent unmet treatment needs. While pharmacological and psychological interventions continue to advance, many…
-
Journal Article
Benzodiazepine receptor agonist deprescribing principles for long-term use and dependence: modified Delphi recommendations from a multi-disciplinary expert panel
Background: Benzodiazepine receptor agonists (BZRA) are frequently tapered because of risk of dependence and hazards of use in ageing. Standard tapering protocols may fail or result in harm from improper utilization of pharmacologic principles, lack of recognition of withdrawal and/or failures in…
-
Journal Article
Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect
Background: The potential of aripiprazole to reverse amisulpride-induced hyperprolactinemia has yet to be established. Objectives: To investigate whether adjunctive aripiprazole treatment can reverse amisulpride-induced prolactin (PRL) elevation. Design: This study was a single-arm retrospective…
-
Journal Article
Cariprazine augmentation for negative symptoms of schizophrenia: a prospective analysis and literature review
Cariprazine is effective in a number of conditions and has shown efficacy in the treatment of negative symptoms. Data on its use as an adjunct to other antipsychotics is growing. To evaluate the effectiveness of add-on cariprazine in patients with predominant negative symptoms, we assessed a series…
-
Journal Article
The mechanism of action and clinical efficacy of xanomeline-trospium in schizophrenia: A comprehensive review
This narrative review summarizes the latest clinical evidence on xanomeline-trospium in schizophrenia, a first-in-class centrally acting dual-target muscarinic receptor modulator. Xanomeline-trospium combines the muscarinic receptor agonist xanomeline, with with functional preference for M1/M4…
-
Journal Article
Anticholinergic burden and its predictors among patients with schizophrenia in Northwest Ethiopia: An institutional-based cross sectional study
Background Many drugs prescribed for individuals with schizophrenia have anticholinergic effects. When these medications are used together, they can create a substantial overall Anticholinergic Burden (ACB). Objective The aim of this study was to assess the prevalence of ACB and its predictors…
-
Journal Article
Efficacy and safety of semaglutide versus placebo for people with schizophrenia spectrum disorders with obesity or early-stage metabolic abnormalities: A systematic review and meta-analysis of randomized controlled studies
Background Individuals with schizophrenia spectrum disorders are at increased risk of cardiometabolic complications, largely due to antipsychotic-associated metabolic effects. Effective management strategies remain limited. Semaglutide, a glucagon-like peptide-1 receptor agonist, has shown…
-
Journal Article
Clinical response to clozapine in Black people with psychosis: A secondary analysis of an open-label clinical trial
Background Clozapine is the most effective treatment for people with treatment-resistant schizophrenia (TRS). However, clozapine is underutilized, and there are stark racial disparities: Black people with psychosis are less likely to receive clozapine than White people with psychosis. Because of…
-
Journal Article
Efficacy and safety of ecopipam for Tourette syndrome: An updated systematic review and meta-analysis of randomized controlled trials
Background Tourette syndrome is a neurodevelopmental disorder characterized by persistent motor and vocal tics. Dopamine D2 receptor antagonists can reduce tic severity but are frequently limited by metabolic, sedative, and extrapyramidal adverse effects. Ecopipam is a selective dopamine D1/D5…
-
Journal Article
Psychoactive drug use and substance-induced psychosis: Emerging challenges in a low-middle-income country
Plain language summary The Ministry of Home Affairs, Nepal , “The National Master Plan on Prevention and Control of Narcotic Drugs 2012-2019″ reports that cannabis accounts for the highest prevalence of initial narcotic drug use (80.4%), followed by diazepam (9.4%). Narcotic drug users increased by…
-
Journal Article
Same sample, different result: Variation in clozapine assay measurement in four UK laboratories
Background Laboratory measurement of clozapine blood concentrations is central to safe and effective treatment and is commonly assumed to be accurate and reproducible across providers. Chromatographic assays require batch-specific setup and are performed using different equipment and techniques…
-
Journal Article
Therapeutic apartheid: a cross-sectional assessment of estimated cost, accessibility, affordability, and availability among psychotropic medications across 25 regions
Introduction: Mental disorders affect approximately 20% of the global population and remain a leading cause of disability and premature mortality. Despite pharmacotherapy being central to treatment, access to psychotropic medicines is highly unequal, particularly in low- and middle-income…
-
Journal Article
Informing the patient of the placebo option: an ethical necessity likely to reduce inappropriate psychotropic prescriptions?
The growing interest in deprescribing drugs highlights the importance of re-evaluating prescriptions, but also of limiting inappropriate prescribing. This paper reflects on the ethical use of a placebo as a way of limiting inappropriate prescribing. We focus on psychotropic drugs, but our reasoning…